Krystal Biotech, Inc.KRYSNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +116.26% | +94.88% | +36.65% | +16.65% | +17.52% |
| Gross Profit Growth | +128.23% | +94.15% | +38.28% | +19.41% | +11.60% |
| EBITDA Growth | +252.96% | +409.24% | +76.94% | +35.97% | -7.74% |
| Operating Income Growth | +1218.64% | +0.00% | +358.87% | +84.43% | +7.39% |
| Net Income Growth | +423.23% | +3734.01% | +146.23% | +192.00% | +13.02% |
| EPS Growth | +409.68% | +4033.33% | +146.30% | +188.42% | +12.03% |
| EPS Diluted Growth | +406.67% | +3900.00% | +143.40% | +192.31% | +11.84% |
| Weighted Average Shares Growth | +2.08% | +1.84% | +1.09% | +0.83% | +0.66% |
| Weighted Average Shares Diluted Growth | +3.70% | +1.98% | +0.38% | -0.23% | +0.23% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +94.92% | +0.00% | -32.62% | +46.68% |
| Free Cash Flow Growth | +0.00% | +69.30% | +0.00% | -34.35% | +44.82% |
| Receivables Growth | +149.16% | +122.22% | +7.95% | +33.23% | +21.65% |
| Inventory Growth | +279.50% | +171.29% | +154.87% | +102.53% | +52.69% |
| Asset Growth | +29.02% | +25.91% | +24.05% | +26.24% | +26.33% |
| Book Value per Share Growth | +19.06% | +20.98% | +22.71% | +27.40% | +28.02% |
| Debt Growth | -10.29% | +22.38% | +25.94% | +27.22% | +28.62% |
| R&D Expense Growth | +18.94% | +30.10% | -7.53% | -2.41% | +19.76% |
| SG&A Expenses Growth | +34.53% | +25.58% | +27.27% | +30.87% | +31.94% |